Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?

Pediatric Hematology and Oncology

Volumn 31, Issue 3, 2014, Pages 237-252

  Basar, Evic Zeynep ^a   Corapcioglu, Funda ^a   Babaoglu, Kadir ^a   Anik, Yonca ^a   Gorur Daglioz, Gozde ^a   Dedeoglu, Reyhan ^b  

^a KOCAELI UNIVERSITY   (Turkey)

^b DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Anthracycline; Cardiac magnetic resonance imaging; Cardiotoxicity; Echocardiography; Radionuclide ventriculography

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PREDNISONE; VINCRISTINE; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; ALGORITHM; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVOR; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CHILD; CHILDHOOD CANCER; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DOPPLER DEVICE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EVALUATION STUDY; FEMALE; FOLLOW UP; HOLTER MONITOR; HOLTER MONITORING; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE SCANNER; PHYSICAL EXAMINATION; RADIOISOTOPE VENTRICULOGRAPHY; SOLID TUMOR; SYMPTOMATOLOGY; CANCER STAGING; COMPARATIVE STUDY; NEOPLASMS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; PROGNOSIS; SURVIVAL RATE; SURVIVOR; YOUNG ADULT;

ADOLESCENT; ADULT; ALGORITHMS; ANTHRACYCLINES; CARDIOTOXICITY; CHILD; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; RADIONUCLIDE VENTRICULOGRAPHY; SURVIVAL RATE; SURVIVORS; YOUNG ADULT;

EID: 84897088552     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2013.851753     Document Type: Article

References (47)

1. Hale JP, Lewis IJ. Anthracyclines: Cardiotoxicity and its prevention. Arch Dis Child. 1994;71:457-462
2. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94:525-533
3. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. 1998;25:72-85
4. Hitchcock-Bryan S, Gelber RD, Cassady Jr, Sallan SE. The impact of induction anthracycline on long-Term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1986;14:211-215
5. Dreyer ZE, Blatt J, Bleyer A. Late effects of childhood cancer and its treatment. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams&Wilkins; 2002:1431-1461
6. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents. Drug Saf. 2000;22:263-302
7. Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukemia. Hematology (Am Soc Hematol Educ Program). 2004;118-145
8. Lown B, Wolf M. Approaches of sudden death from coronary heart disease. Circulation. 1971;46:130-142
9. Sahn DJ, DeMaria A, Kisslo J, Weyman A.The committeeonM-Mode standardisation of theAmerican Society of Echocardiography: Recommendations regarding quantitation in M-Mode echocardiography: Result of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083
10. Mirsky I, Pasipoularides A. Clinical assessment of diastolic function. Prog Cardiovasc Dis. 1990;32:291-318
11. BúLock FA, Mott MG, Martin RP. Left ventricular diastolic dysfunction in children measured by-Doppler echocardiography: Normal values and relation with growth. Br Heart J. 1995;73:334-339
12. Ganz WI, Sridhar KS, Ganz SS, et al. Review of test for monitoring doxorubicin-induced cardiomyopathy. Oncology. 1996;53:461-470
13. Meinardi MT, Van Der Graaf WTA, van Veldhuisen DJ, et al. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev. 1999;25:237-224
14. Murphy PB, Port SC. Radionuclide evaluation of left ventricular function. In: Sandler MP, Coleman RE, Patton JA, Wackers FJTH, Gottschalk A, eds. Diagnostic NuclearMedicine. Philadelphia, PA: LippincottWilliams& Wilkins; 2003:239-271
15. Cerqueira MD, Weissman NJ, Dilsizian V. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals fromthe Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539-542
16. Billingham ME, Masek MA. The pathology of anthracycline cardiotoxicity in children, adolescents and adults. In: Bricker JT, Green DM, D'Angio G, eds. Cardiac Toxicity After Treatment for Childhood Cancer. New York:Wiley-Liss, 1993;17-24
17. VonHoff DD, LayardMW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann InternMed. 1979;91:710-717
18. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.N Engl J Med. 1995;332:1738-1743
19. Swain SM.Adultmulticenter trials usingdexrazoxane to protect against cardiac toxicity. SeminOncol. 1998;25:43-47
20. Iarussi D, Indolfi P, Galderisi M, Bossone E. Cardiac toxicity after anthracycline chemotherapy in childhood. Herz. 2000;25:676-688
21. Schwartz CL, Hobbie WL, Truesdell S, et al. Corrected QT interval prolongation in anthracyclinetreated survivors of childhood cancer. J Clin Oncol. 1993;11:1906-1910
22. Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: A survey of 1273 patients. Cancer Treat Rep. 1979;63:827-834
23. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.N Engl J Med. 1991;324:808-815
24. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics. 1992;89:942-949
25. BúLock FA, Mott MG, Oakhill A, Martin RP. Early identification of anthracycline cardiomyopathy: Possibilities and implications. Arch Dis Child. 1996;75:416-422
26. Wassmuth R, Lentzsch S, Erdbruegger U, et al. Subclinical cardiotoxic effects of anthracyclines as assessed bymagnetic resonance imaging-A pilot study. Am Heart J. 2001;141:1007-1013
27. Mahler F, Ross J Jr, O'Rourke RA, Covell JW. Effects of changes in preload, afterload and inotropic state on ejection and isovolumic phasemeasures of contractility in the conscious dog. Am J Cardiol. 1975;35:626-634
28. Isaaz K, Thompson A, Ethevenot G, Cloez JL.Doppler electrocardiografic mesurement of lowvelocity motion of the left ventricular posterior wall. Am J Cardiol. 1989;64:66-75
29. Oǧuzhan A, Abaci A, Ç;etin S.DokuDoppler ekokardiyografi. Türk J Echocardiography. 2000;2:35-41
30. Kantar M, Levent E, Ç;etingül N, et al. Plasma natriuretic peptides levels and echocardiographic findings in late subclinical anthracycline toxicity. Pediatr Hematol Oncol. 2008;25:723-733
31. Eidem BW, Sapp BG, Suarez CR, Cetta F. Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol. 2001;87:1120-1122
32. Feigenbaum H, ArmstrongWF, Ryan T. Feigenbaum's Echocardiography (6th ed.). Philadelphia, PA: LippincottWilliams-Wilkins; 2005:437-486
33. Elbl L, Hrstkova H, Chaloupka V.The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer. Eur J Pediatr. 2003;162:690-696
34. Mj, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J AmColl Cardiol. 1998;32:865-875
35. Ç;orapcioǧlu F, SarperN, Berk F, et al. Evaluation of anthracycline-induced early left ventricular dysfunction in children with cancer: A comparative study with echocardiography and multigated radionuclide angiography. Pediatr Hematol Oncol. 2006;23:71-80
36. Leong DP, De Pasquale CG, Selvanayagam JB. Heart failure with normal ejection fraction: The complementary roles of echocardiography andCMRimaging. JACC Cardiovasc Imaging. 2010;3:409-420
37. Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicine cardiotoxicity: Interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989;118:92-98
38. Eidem BW, McMahon CJ, Cohen RR, et al. Impact of cardiac growth on Doppler tissue imaging velocities: A study in healthy children. J Am Soc Echocardiogr. 2004;17(3):212-221
39. Ganz WI, Sridhar KS, Ganz SS, et al. Review of test for monitoring doxorubicin-induced cardiomyopathy. Oncology. 1996;53:461-470
40. Steinberg JS, Wasserman AG. Radionuclide ventriculography for evaluation and prevention of doxorubicin cardiotoxicity. Clin Ther. 1985;7:660-667
41. Shureiqi I, Cantor SB, Lippman SM, et al. Clinical and economic impact ofmultiple gated acquisition scan monitoring during anthracycline therapy. Br J Cancer. 2002;86:226-232
42. Agarwala S, Kumar R, Bhatnagar V, et al. High incidence of adriamycin cardiotoxicity in children even at lowcumulative doses: Role of radionuclide cardiac angiography. JPediatr Surg. 2000;35:1786-1789
43. Higgins CB.Which standard has the gold? J Amer Coll Cardiol. 1992;19:1608-1609
44. Oberholzer K, Kunz RP, Dittrich M, Thelen M. Anthracycline-induced cardiotoxicity: Cardiac MRI after treatment for childhood cancer. [Article in German]. Rofo. 2004;176:1245-1250
45. Stoodley PW, Richards DA, Meikle SR, et al. The potential role of echocardiographic strain imaging for evaluating cardiotoxicity due to cancer therapy. Heart Lung Circ. 2011;20:3-9
46. Stoodley PW, Richards DAB, Hui R, Boyd A, Harnett PR, Meikle SR. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. Eur J Echocardiogr. 2011;12:945-952
47. Constine LS, Schwartz RG, Savage DE, et al. Cardiac function, perfusion, andmorbidity in irradiated long-Termsurvivors of Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1997;39:897-906.